Multi-source biosimilar competition in Europe to Roche’s Avastin (bevacizumab) that debuted last year led sales of the oncology biologic to nosedive by 68% to CHF138m ($151m) in the first-quarter of 2021, as Roche management conceded that “most of the Avastin business in Europe is now gone.”
In June last year, Pfizer’s Zirabev (bevacizumab) and Amgen’s Mvasi (bevacizumab) biosimilars began shipping in major EU markets, although Roche...






